

## Pegylated synthetic human c-peptide

|                      |   |
|----------------------|---|
| Cat. No.:            | HY-P4063  |
| CAS No.:             | 1350661-05-0  |
| Molecular Formula:   | C <sub>129</sub> H <sub>211</sub> N <sub>35</sub> O <sub>48</sub>   |
| Molecular Weight:    | 3018.52   |
| Sequence:            | Glu-Ala-Glu-Asp-Leu-Gln-Val-Gly-Gln-Val-Glu-Leu-Gly-Gly-Gly-Pro-Gly-Ala-Gly-Ser-Leu<br>-Gln-Pro-Leu-Ala-Leu-Glu-Gly-Ser-Leu-Gln |
| Sequence Shortening: | EAEDLQVGQVELGGGPGAGSLQPLALEGSLQ   |
| Target:              | Others  |
| Pathway:             | Others  |
| Storage:             | Please store the product under the recommended conditions in the Certificate of Analysis.                                       |

### BIOLOGICAL ACTIVITY

|             |  |
|-------------|--|
| Description | Pegylated synthetic human c-peptide retains bioactivity comparable to that of natural (i.e. non-polyethylene glycolated) C-peptides and has a prolonged circulating residence time in plasma for use in diabetic peripheral neuropathy studies <sup>[1]</sup> .  |
| In Vivo     | Pegylated synthetic human c-peptide (CBX129801) (s.c., 0.4, 1.33 or 4.0 mg/kg/wk, 39 weeks) can lead to cytoplasmic infiltration of vacuolated macrophages in the tissue at the injection site and drainage of axillary lymph nodes after administration of the drug without systemic macrophage vacuolation in <i>Macaca fascicularis</i> <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |

### REFERENCES

[1]. Dennis Naas, et al. A 9-Month Toxicity and Toxicokinetic Assessment of Subcutaneous Pegylated Human C-peptide (CBX129801) in Cynomolgus Monkeys. *Int J Toxicol.* 2015 Jul-Aug;34(4):318-24.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA